Exhibit 2.1 ----------- ASSET PURCHASE AND LICENSE AGREEMENT BY AND AMONGAsset Purchase and License Agreement • August 15th, 2001 • KFX Inc • Industrial organic chemicals • Delaware
ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • August 10th, 2018 • Eton Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS ASSET PURCHASE AND LICENSE AGREEMENT (this “Agreement”) dated as of May 9, 2017 (the “Effective Date”), is entered into between IMPRIMIS PHARMACEUTICALS, INC., a Delaware corporation (“Imprimis”), with a place of business at 12264 El Camino Real, Suite 350, San Diego, California 92130, and ETON PHARMACEUTICALS, INC., a Delaware corporation (“Eton”), with a place of business at 12264 El Camino Real, Suite 350, San Diego, California 92130. The parties hereby agree as follows:
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed; and is indicated with brackets where the information has been omitted from the filed...Asset Purchase and License Agreement • April 24th, 2019 • Mabvax Therapeutics Holdings, Inc. • Pharmaceutical preparations • New York
This Asset Purchase and License Agreement (the “Agreement”) is made on July 4, 2018 (the “Effective Date”) under the terms and conditions herein by and between Boehringer Ingelheim International GmbH having a principal place of business at Binger Strasse 173, 55216 Ingelheim, Germany, (hereinafter referred to as “BII”), MabVax Therapeutics Holdings, Inc., a corporation organized and existing under the laws of Delaware, USA, having its principal place of business at 11535 Sorrento Valley Road, Suite 400, San Diego, California 92121, and MabVax Therapeutics Inc., a corporation organized and existing under the laws of Delaware, USA, having its principal place of business at 11535 Sorrento Valley Road, Suite 400, San Diego, California 92121 (MabVax Therapeutics Holdings, Inc., and MabVax Therapeutics Inc. hereinafter referred to as “MABVAX”).
EX-10.2 3 ex10-2.htm AMENDED AND RESTATED ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • May 5th, 2020 • California
THIS AMENDED AND RESTATED ASSET PURCHASE AND LICENSE AGREEMENT (this “Agreement”) dated as of the last date provided on the signature page (the “Restatement Date”), is entered into between IMPRIMIS PHARMACEUTICALS, INC., a Delaware corporation (“Imprimis”), with a place of business at 12264 El Camino Real, Suite 350, San Diego, California 92130, and SURFACE Pharmaceuticals, Inc., a Delaware corporation (“Surface”), with a place of business at 12264 El Camino Real, Suite 350, San Diego, California 92130.
EX-10.1 2 dex101.htm ASSET PURCHASE AND LICENSE AGREEMENT ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • May 5th, 2020 • Delaware
This Asset Purchase and License Agreement (this “Agreement”), dated the 25th day of March, 2005 (the “Effective Date”), is by and among Sunol Molecular Corporation, a Delaware corporation having its principal offices at 2810 North Commerce Parkway, Miramar, Florida 33025-3958 (“Seller”), Tanox, Inc., a Delaware corporation having its principal offices at 10301 Stella Link, Houston, Texas 77025 (“Purchaser”), and solely with respect to the Sections and Articles hereof set forth in Section 15.14 below, Altor Bioscience Corporation, a Delaware corporation having its principal offices at 2810 North Commerce Parkway, Miramar, Florida 33025-3958 (“Altor”).
EX-10.3 3 dex103.htm ASSET PURCHASE AND LICENSE AGREEMENT, DATED AS OF JUNE 8, 2007 CONFIDENTIAL Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting...Asset Purchase and License Agreement • May 5th, 2020 • Delaware
THIS AGREEMENT, made this 8th of June, 2007, (“Signing Date”) by and among 3M COMPANY (hereinafter “3M”), 3M INNOVATIVE PROPERTIES COMPANY (hereinafter “3M IPC”), Delaware corporations having offices at 3M Center, St. Paul, Minnesota 55144, USA and COLEY PHARMACEUTICAL GROUP, INC. a Delaware corporation having its address at 93 Worcester Street, Suite 101, Wellesley, MA 02481 USA (hereinafter “COLEY”). 3M IPC is a wholly owned subsidiary of 3M. Hereinafter a reference to “3M” or “COLEY” shall include their respective Affiliates where performance would be expected from or required by an Affiliate.
EX-10.1 2 dex101.htm ASSET PURCHASE AND LICENSE AGREEMENT EXECUTION COPYAsset Purchase and License Agreement • May 5th, 2020 • New York
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
EX-2.1 3 d566761dex21.htm EX-2.1 EXECUTION VERSION CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT...Asset Purchase and License Agreement • May 5th, 2020
each a “party” and, together, the “parties”. Save as where otherwise provided, Glaxo Group and GSK IPD shall be jointly referred to as the “Seller”.
ASSET PURCHASE AND LICENSE AGREEMENT BY AND BETWEEN ALKERMES, INC. AND CORREGIDOR THERAPEUTICS, INC. DECEMBER 27, 2010Asset Purchase and License Agreement • August 26th, 2014 • Civitas Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Asset Purchase and License Agreement (the “Agreement”) is made effective as of the 27th day of December 2010 (the “Effective Date”) by and between Alkermes, Inc., a Pennsylvania corporation having a principal place of business at 852 Winter Street, Waltham, Massachusetts 02451 (“Alkermes”), and Corregidor Therapeutics, Inc., a Delaware corporation with its principal place of business located at 384 Powder Mill Road, Concord, MA 01742 (“Corregidor”). Alkermes and Corregidor are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Asset Purchase and LICENcE AgreementAsset Purchase and License Agreement • December 10th, 2014 • England
ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • September 18th, 2017 • National General Holdings Corp. • Fire, marine & casualty insurance • New York
AMTRUST NORTH AMERICA, INC., a Delaware corporation, with a business address of 800 Superior Avenue, Cleveland, Ohio 44114 (“AMTRUST” or “SELLER”); and
ContractAsset Purchase and License Agreement • August 29th, 2013 • Heska Corp • Biological products, (no disgnostic substances) • New York
Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act. Omitted information, marked “[***]” in this exhibit, has been filed with the Securities and Exchange Commission together with such request for confidential treatment.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. ASSET PURCHASE AND...Asset Purchase and License Agreement • October 3rd, 2024 • Innovative Solutions & Support Inc • Services-computer programming services • New York
THIS ASSET PURCHASE AND LICENSE AGREEMENT (this “Agreement”) is made this 27th day of September 2024, by and between Innovative Solutions and Support, Inc., a Pennsylvania corporation, (“Purchaser”), and Honeywell International Inc., a Delaware corporation (“Seller” and together with the Purchaser, the “Parties” and each a “Party”).
ASSET PURCHASE AND LICENSE AGREEMENT BY AND BETWEEN ALKERMES, INC. AND CORREGIDOR THERAPEUTICS, INC. DECEMBER 27, 2010Asset Purchase and License Agreement • February 27th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. SUCH OMITTED PORTIONS, WHICH ARE MARKED WITH BRACKETS [ ] AND AN ASTERISK*, HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
ASSET PURCHASE AND LICENSE AGREEMENT BY AND BETWEEN NUPATHE INC., AND TRAVANTI PHARMA INC.Asset Purchase and License Agreement • June 15th, 2010 • Nupathe Inc. • Pharmaceutical preparations • Delaware
Asset Purchase and License Agreement (this “Agreement”), dated as of July 8, 2008, by and between Travanti Pharma Inc., a Minnesota corporation with a principal place of business at 2520 Pilot Knob Road, Suite 100, Mendota Heights, MN 55120 (“Travanti”), and NuPathe Inc., a Delaware corporation with a principal place of business at 227 Washington Street, Suite 200, Conshohocken, PA 19428 (“NuPathe”).
ASSET PURCHASE AND LICENSE AGREEMENT between:Asset Purchase and License Agreement • February 11th, 2003 • Restoragen Inc • Pharmaceutical preparations • Delaware
This Asset Purchase and License Agreement (the “Agreement”) is entered into and effective as of December 24, 2002 by and between Restoragen, Inc., a Delaware corporation, located at 3820 NW 46th Street, Lincoln, Nebraska 68524 (“Restoragen”), and Amylin Pharmaceuticals, Inc., a Delaware corporation, located at 9373 Towne Centre Drive, San Diego, California 92121 (“Amylin”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • May 27th, 2003 • Restoragen Inc • Pharmaceutical preparations • Delaware
THIS ASSET PURCHASE AND LICENSE AGREEMENT (the “Agreement”) is entered into as of March 24, 2003 by and between RESTORAGEN, INC., a Delaware corporation, located at 5701 S. 34th Street, Suite 203, Lincoln, Nebraska 68516 (“Restoragen”) and COOLIDGE & COMPANY, INC., a Delaware corporation, located at 173 Beebe Hill Road, Falls Village, Connecticut 06031. It is contemplated that, prior to the Closing, Coolidge & Company, Inc. will assign this Agreement to a newly formed entity called GHRCO, Inc. All references to “GHRCO” in this Agreement shall refer to Coolidge & Company, Inc. or to GHRCO, Inc. following such assignment. Certain capitalized terms used in this Agreement are defined in Exhibit A.
ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • September 9th, 2016 • Biodel Inc • Pharmaceutical preparations • Delaware
This ASSET PURCHASE AND LICENSE AGREEMENT (this “Agreement”) is entered into as of September 2, 2016 (the “Effective Date”) by and among Unilife Corporation, a Delaware corporation (“Unilife”), Unilife Medical Solutions, Inc., a Delaware corporation and a subsidiary of Unilife (“UMS” and, together with Unilife, the “Unilife Parties”), and Biodel Inc., a Delaware corporation (“Biodel”). Each of Unilife, UMS and Biodel may be referred to herein as a “Party” and, together, as the “Parties.”
1 Exhibit 10.153 ASSET PURCHASE AND LICENSE AGREEMENT This Asset Purchase and License Agreement ("Agreement") is made as of this 15th day of February, 2000, by and between Mycogen Corporation, a California corporation ("Seller"), and Ecogen Inc., a...Asset Purchase and License Agreement • March 1st, 2000 • Ecogen Inc • Agricultural chemicals • Indiana
ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • May 30th, 2008 • Acxiom Corp • Services-computer processing & data preparation • Massachusetts
ASSET PURCHASE AND LICENSE AGREEMENT (this “Agreement”) dated as of December 29, 2005 (the “Effective Date”), by and between Acxiom Corporation, a Delaware corporation (“Acxiom” or “Seller”), and EMC Corporation, a Massachusetts corporation, and EMC (Benelux) B.V., S.à.r.l., a Luxembourg limited liability company (together, "EMC" or “Buyer”).
AMENDMENT NO. 1 to ASSET PURCHASE AND LICENSE AGREEMENT between HONEYWELL INTERNATIONAL INC. and INNOVATIVE SOLUTIONS AND SUPPORT, INC.Asset Purchase and License Agreement • August 14th, 2024 • Innovative Solutions & Support Inc • Services-computer programming services
Honeywell International Inc., a Delaware corporation (“Seller”) and Innovative Solutions and Support, Inc., a Pennsylvania corporation, (“Purchaser”) entered into an Asset Purchase and License Agreement, dated June 30, 2023, (the “Main Agreement”).
ContractAsset Purchase and License Agreement • May 5th, 2020 • New York
EX-10.1 2 ex10-1.htm ASSET PURCHASE AND LICENSE AGREEMENT CONFIDENTIAL TREATMENT REQUESTED Exhibit 10.1 ASSET PURCHASE AND LICENSE AGREEMENT by and between BOEHRINGER INGELHEIM INTERNATIONAL GMBH and MABVAX THERAPEUTICS HOLDINGS, INC. and MABVAX THERAPEUTICS, INC. BII Contract No: [***] Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED Table of Contents
TRANSITION AMENDMENT BETWEEN EMC CORPORATION AND ACXIOM CORPORATIONAsset Purchase and License Agreement • May 30th, 2008 • Acxiom Corp • Services-computer processing & data preparation • Massachusetts
This Transition Amendment (this “Amendment”) is made and entered into as of March 31, 2008 (the “Amendment Effective Date”), by and between Acxiom Corporation, a Delaware corporation, with a principal address of 601 East 3rd Street, Little Rock, AR 72201 (“Acxiom”), and EMC Corporation, a Massachusetts corporation with an office at 176 South Street, Hopkinton, Massachusetts 01748 and EMC (Benelux) B.V., S.à.r.l., a Luxembourg limited liability company (together “EMC”).
ASSET PURCHASE AND LICENSE AGREEMENT THIS ASSET PURCHASE AND LICENSE AGREEMENT (the "Agreement") is made this 15th day of November, 2005, by and among CALYPTE BIOMEDICAL CORPORATION, a Delaware corporation ("Seller"), and MAXIM BIOMEDICAL, INC., a...Asset Purchase and License Agreement • November 21st, 2005 • Calypte Biomedical Corp • Laboratory analytical instruments • Delaware
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH IMMATERIAL AND THE TYPE OF INFORMATION THAT INNOVATIVE SOLUTIONS AND SUPPORT, INC. TREATS AS CONFIDENTIAL. ACCORDINGLY, SUCH INFORMATION HAS BEEN OMITTED AND REPLACED WITH...Asset Purchase and License Agreement • August 14th, 2024 • Innovative Solutions & Support Inc • Services-computer programming services
Honeywell International Inc., a Delaware corporation (“Seller”) and Innovative Solutions and Support, Inc., a Pennsylvania corporation (“Purchaser”) entered into an Asset Purchase and License Agreement, dated June 30, 2023, (the “Agreement”), and Amendment 1 to the Main Agreement, dated October 12, 2023 (“Amendment 1” ) and Amendment 2 to the Main Agreement, dated March 24, 2024 (“Amendment 2”, together with Amendment 1 and the Agreement, the “Main Agreement”).
ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • May 18th, 2011 • Human Pheromone Sciences Inc • Perfumes, cosmetics & other toilet preparations • California
THIS ASSET PURCHASE AND LICENSE AGREEMENT (this “Agreement”) is made and entered into as of this May 16, 2011 (the “Effective Date”) by and between Human Pheromone Sciences, Inc., a California corporation (“Grantor”) and CrowdGather Inc., a Nevada corporation (“Grantee”), individually “the Party, together “the Parties”;
AMENDMENT TO ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • February 27th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS AMENDMENT (the “Amendment”) is made and entered into as of December 9, 2011 to the Asset Purchase and License Agreement (the “Agreement”) made and entered into as of December 27, 2010 by and between Civitas Therapeutics, Inc., a Delaware corporation having its principal office at 190 Everett Avenue, Chelsea, MA 02150 (“Civitas”), and Alkermes, Inc., a Pennsylvania corporation having its principal office at 852 Winter Street, Waltham, MA 02451 (“Alkermes”) (any terms used but not defined herein shall have the meaning set forth in the Agreement).
AMENDMENT TO ASSET PURCHASE and LICENSE AGREEMENTAsset Purchase and License Agreement • August 7th, 2019 • Heska Corp • In vitro & in vivo diagnostic substances
This AMENDMENT TO ASSET PURCHASE and LICENSE AGREEMENT (this "Amendment") is entered into effective upon the date of last signature (the "Amendment Effective Date"), by and between:
ASSET PURCHASE AND LICENSE AGREEMENT BY AND BETWEEN ASTRONOVA, INC. AND HONEYWELL INTERNATIONAL INC. SEPTEMBER 28, 2017 License Agreement No. 2017-8072 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION....Asset Purchase and License Agreement • October 4th, 2017 • AstroNova, Inc. • Computer peripheral equipment, nec • New York
THIS ASSET PURCHASE AND LICENSE AGREEMENT (this “Agreement”) is made this 28th day of September 2017, by and between AstroNova, Inc., a Rhode Island corporation, (“Purchaser”), and Honeywell International Inc., a Delaware corporation (“Seller” and together with the Purchaser, the “Parties” and each a “Party”).
ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • May 15th, 2018 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS ASSET PURCHASE AND LICENSE AGREEMENT (this “Agreement”) dated as of the last date provided on the signature page (the “Effective Date”), is entered into between IMPRIMIS PHARMACEUTICALS, INC., a Delaware corporation (“Imprimis”), with a place of business at 12264 El Camino Real, Suite 350, San Diego, California 92130, and SURFACE Pharmaceuticals, Inc., a Delaware corporation (“Surface”), with a place of business at 12264 El Camino Real, Suite 350, San Diego, California 92130. The parties hereby agree as follows:
ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • August 19th, 2008 • Progressive Gaming International Corp • Miscellaneous manufacturing industries • Nevada
This Asset Purchase and License Agreement (this “Agreement”) is made and entered into as of August 15, 2008 (the “Effective Date”), by and between Progressive Gaming International Corporation (“PGIC”), a Nevada corporation, and IGT (“IGT”), a Nevada corporation (each a “Party” and collectively the “Parties”).
ASSET PURCHASE AND LICENSE AGREEMENT by and between Nanometrics Incorporated and Toho Technology Corporation Dated September 14th, 2005Asset Purchase and License Agreement • November 21st, 2005 • Nanometrics Inc • Measuring & controlling devices, nec • California
This Asset Purchase and License Agreement (this “Agreement”) is entered into as of September 14th (the “Effective Date”) by and between Nanometrics Incorporated, a California corporation whose principal place of business is 1550 Buckeye Drive, Milpitas, California (“Nanometrics”) and Toho Technology Corporation, a Kabushiki Kaisha organized under the laws of Japan with a place of business at 3-10-22 Sakae, Naka-ku, Nagoya Aichi 460-0008, Japan (“Toho”) (each, a “Party” and together, the “Parties”).
RECITALSAsset Purchase and License Agreement • March 19th, 2001 • Intrac Inc • Nevada
Asset Purchase and LICENcE AgreementAsset Purchase and License Agreement • September 19th, 2014 • England
ASSET PURCHASE AND LICENSE AGREEMENT by and between BOEHRINGER INGELHEIM INTERNATIONAL GMBH and MABVAX THERAPEUTICS HOLDINGS, INC. and MABVAX THERAPEUTICS, INC. BII Contract No: [***]Asset Purchase and License Agreement • November 13th, 2018 • Mabvax Therapeutics Holdings, Inc. • Pharmaceutical preparations • New York
This Asset Purchase and License Agreement (the “Agreement”) is made on July 4, 2018 (the “Effective Date”) under the terms and conditions herein by and between Boehringer Ingelheim International GmbH having a principal place of business at Binger Strasse 173, 55216 Ingelheim, Germany, (hereinafter referred to as “BII”), MabVax Therapeutics Holdings, Inc., a corporation organized and existing under the laws of Delaware, USA, having its principal place of business at 11535 Sorrento Valley Road, Suite 400, San Diego, California 92121, and MabVax Therapeutics Inc., a corporation organized and existing under the laws of Delaware, USA, having its principal place of business at 11535 Sorrento Valley Road, Suite 400, San Diego, California 92121 (MabVax Therapeutics Holdings, Inc., and MabVax Therapeutics Inc. hereinafter referred to as “MABVAX”).
